Inhibitors of mTOR

Oncologist

Volumn 15, Issue 12, 2010, Pages 1262-1269

  Klümpen, Heinz Josef ^a   Beijnen, Jos H ^c,d   Gurney, Howard ^e   Schellens, Jan H M ^b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anticancer treatment; Drug review; Everolimus; mTOR inhibitor; Temsirolimus

Indexed keywords

APREPITANT; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXAMETHASONE; DILTIAZEM; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; HISTAMINE H1 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN; NEFAZODONE; PHENOBARBITAL; PHENYTOIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; SOMATOMEDIN C; TELITHROMYCIN; TEMSIROLIMUS; VERAPAMIL; VORICONAZOLE;

AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPNEA; ENZYME ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC POLYMORPHISM; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; LIVER DISEASE; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MOUTH ULCER; ORAL MUCOSAL DISEASE; PHARMACODYNAMICS; PHARMACOGENETICS; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES;

EID: 78650971226     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0196     Document Type: Review

References (69)

1. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858.
2. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: A review of clinical trial data, current usage, and future directions. Transplant Rev 2006;20:1-18.
3. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-726.
4. Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-732.
5. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253:905-909.
6. Brown EJ, Albers MW, Shin TB et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756-758.
7. Choo AY, Yoon SO, Kim SG et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008;105:17414-17419.
8. Kim DH, Sarbassov DD, Ali SM et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-175.
9. Houghton PJ. Everolimus. Clin Cancer Res 2010;16:1368-1372.
10. le Tourneau C, Faivre S, Serova M et al. mTORC1 inhibitors: Is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008;99: 1197-1203.
11. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
12. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
13. Ramalingam SS, Harvey RD, Saba N et al. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 2010;116:3903-3909.
14. Milton DT, Riely GJ, Azzoli CG et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007; 110:599-605.
15. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-688.
16. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: Do all roads pass through mTOR? Oncogene 2006;25:6347-6360.
17. Mamane Y, Petroulakis E, LeBacquer O et al. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-6422.
18. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135.
19. Shi Y, Frankel A, Radvanyi LG et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995;55:1982-1988.
20. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12:122-127.
21. Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-759.
22. Mondesire WH, Jian W, Zhang H et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10:7031-7042.
23. Shinohara ET, Cao C, Niermann K et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005;24:5414-5422.
24. Wu C, Wangpaichitr M, Feun L et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4:25.
25. Gligorov J, Azria D, Namer M et al. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: Focus on clinical trials and perspectives. Crit Rev Oncol Hematol 2007;64:115-128.
26. Lunardi G, Armirotti A, Nicodemo M et al. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series. Clin Ther 2009;31: 1812-1819.
27. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95.
28. Kovarik JM, Noe A, Berthier S et al. Clinical development of an everolimus pediatric formulation: Relative bioavailability, food effect, and steady-state pharmacokinetics. J Clin Pharmacol 2003;43:141-147.
29. Kovarik JM, Hsu CH, McMahon L et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications. Clin Pharmacol Ther 2001;70:247-254.
30. Kovarik JM, Hartmann S, Hubert M et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002;42:222-228.
31. Kovarik JM, Hartmann S, Figueiredo J et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002;36:981-985.
32. Crowe A, Bruelisauer A, Duerr L et al. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999;27: 627-632.
33. Yacyshyn BR, Bowen-Yacyshyn MB, Pilarski LM. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol 1996;43:449-455.
34. Lampen A, Zhang Y, Hackbarth I et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998;285:1104-1112.
35. Kovarik JM, Sabia HD, Figueiredo J et al. Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clin Pharmacol Ther 2001;70:425-430.
36. Kovarik JM, Kahan BD, Kaplan B et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001;69:48-56.
37. Zimmerman JJ, Lasseter KC, Lim HK et al. Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J Clin Pharmacol 2005;45:1368-1372.
38. Yatscoff R, LeGatt D, Keenan R et al. Blood distribution of rapamycin. Transplantation 1993;56:1202-1206.
39. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-2347.
40. Jacobsen W, Serkova N, Hausen B et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001;33:514-515.
41. Taylor PJ, Franklin ME, Graham KS et al. A HPLC-mass spectrometric method suitable for the therapeutic drug monitoring of everolimus. J Chromatogr B Analyt Technol Biomed Life Sci 2007;848:208-214.
42. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918.
43. Punt CJ, Boni J, Bruntsch U et al. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003;14:931-937.
44. O'Donnell A, Faivre S, Burris HA 3rd et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26:1588-1595.
45. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. J Clin Oncol 2005;23:5294-5304.
46. Boni JP, Leister C, Burns J et al. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008;98:1797-1802.
47. Boni J, Abbas R, Leister C et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol 2009;64:263-270.
48. Awada A, Cardoso F, Fontaine C et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91.
49. European Medicines Agency. Torisel: Summary of Product Characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000799/WC500039912.pdf, accessed October 16, 2010.
50. Lunardi G, Vannozzi MO, Armirotti A et al. Temsirolimus in patients with renal cancer on hemodialysis. J Clin Oncol 2008;26:5652-5653.
51. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
52. Boni JP, Leister C, Bender G et al. Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005;77:76-89.
53. Anglicheau D, Le Corre D, Lechaton S et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005;5:595-603.
54. Djebli N, Picard N, Rérolle JP et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007;17:321-330.
55. Mourad M, Mourad G, Wallemacq P et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005;80:977-984.
56. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66: 1500-1508.
57. Shi Y, Yan H, Frost P et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-1540.
58. Phung TL, Ziv K, Dabydeen D et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10:159-170.
59. Stoeltzing O, Meric-Bernstam F, Ellis LM. Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cell 2006;10:89-91.
60. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006;6:729-734.
61. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007;6:2139-2148.
62. Chapuis N, Tamburini J, Green AS et al. Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010;16:5425-5435.
63. Dowling RJ, Zakikhani M, Fantus IG et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-10812.
64. Peralba JM, DeGraffenried L, Friedrichs W et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003;9:2887-2892.
65. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-261.
66. Tanaka C, O'Reilly T, Kovarik JM et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26:1596-1602.
67. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278-2287.
68. Tabernero J, Rojo F, Calvo E et al. Dose and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-1610.
69. Kuhn JG, Chang SM, Wen PY et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clinical Cancer Res 2007;13:7401-7406.